Dent RA - Search Results

1

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.

Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN. Clemons MJ, et al. Among authors: dent ra. Breast Cancer Res Treat. 2014 Jul;146(1):153-62. doi: 10.1007/s10549-014-3015-6. Epub 2014 Jun 13. Breast Cancer Res Treat. 2014. PMID: 24924416 Clinical Trial.

2

Adjuvant trastuzumab for breast cancer.

Dent R, Clemons M. Dent R, et al. BMJ. 2005 Nov 5;331(7524):1035-6. doi: 10.1136/bmj.331.7524.1035. BMJ. 2005. PMID: 16269471 Free PMC article. No abstract available.

3

Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.

Dent R, Clemons M. Dent R, et al. Cancer Treat Rev. 2006 Apr;32(2):144-8. doi: 10.1016/j.ctrv.2006.01.005. Epub 2006 Mar 6. Cancer Treat Rev. 2006. PMID: 16517084 Clinical Trial. No abstract available.

4

Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Dent R, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045. Clin Cancer Res. 2007. PMID: 17671126

5

Pattern of metastatic spread in triple-negative breast cancer.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Dent R, et al. Breast Cancer Res Treat. 2009 May;115(2):423-8. doi: 10.1007/s10549-008-0086-2. Epub 2008 Jun 10. Breast Cancer Res Treat. 2009. PMID: 18543098

6

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Kassam F, et al. Clin Breast Cancer. 2009 Feb;9(1):29-33. doi: 10.3816/CBC.2009.n.005. Clin Breast Cancer. 2009. PMID: 19299237

7

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.

Parissenti AM, Chapman JA, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, Pritchard KI, Shepherd LE, Trudeau ME. Parissenti AM, et al. Breast Cancer Res Treat. 2010 Jan;119(2):347-56. doi: 10.1007/s10549-009-0531-x. Breast Cancer Res Treat. 2010. PMID: 19771508 Clinical Trial.

8

Impact of biomarkers on clinical trial risk in breast cancer.

Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Parker JL, et al. Breast Cancer Res Treat. 2012 Nov;136(1):179-85. doi: 10.1007/s10549-012-2247-6. Epub 2012 Sep 25. Breast Cancer Res Treat. 2012. PMID: 23007573

9

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Dent RA, et al. Breast Cancer Res. 2013;15(5):R88. doi: 10.1186/bcr3484. Breast Cancer Res. 2013. PMID: 24063698 Free PMC article. Clinical Trial.

10

Platinum-based chemotherapy in triple-negative advanced breast cancer.

Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Villarreal-Garza C, et al. Breast Cancer Res Treat. 2014 Aug;146(3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8. Breast Cancer Res Treat. 2014. PMID: 25001611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page